Interestingly, we observed an increased frequency of CD38+CD56brightCD16− NK cells in AML, which confirmed previous findings for solid cancers, where CD38-mediated adenosine production by CD56brightCD16− NK cells accounts for a significant CD4+ T cell inhibition [59]. This evidence concerns the gene CD38 and acute myeloid leukemia.